A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production

Hepatology

Volumn 55, Issue 6, 2012, Pages 1662-1672

  Khachatoorian, Ronik ^a   Arumugaswami, Vaithilingaraja ^a,b   Ruchala, Piotr ^a   Raychaudhuri, Santanu ^a   Maloney, Eden M ^c   Miao, Edna ^a   Dasgupta, Asim ^a   French, Samuel W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEAT SHOCK PROTEIN 70; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5A C TERMINAL 34 AMINO ACID PEPTIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BETA SHEET; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENE DELETION; HEPATITIS C VIRUS; IN VITRO STUDY; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; NUCLEOTIDE BINDING SITE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION REGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

BINDING SITES; CELLS, CULTURED; DRUG DESIGN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; PEPTIDE FRAGMENTS; PROTEIN BIOSYNTHESIS; PROTEIN STRUCTURE, TERTIARY; RIBOSOMES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84861570717     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25533     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78.
3. Gambarin-Gelwan M, Jacobson IM. Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. J Viral Hepat 2008; 15: 623-633.
4. McHutchison JG, Patel K. Future therapy of hepatitis C. HEPATOLOGY 2002; 36: S245-S252.
5. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34.
6. Butt AA, Skanderson M, McGinnis KA, Kwoh CK, Justice AC. Real-life rates of treatment completion for HCV. HEPATOLOGY 2007; 46: 364A.
7. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-292.
8. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nature Rev Gastroenterol Hepatol 2011; 8: 69-71.
9. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938.
10. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 2008; 82: 1073-1083.
11. He Y, Yan W, Coito C, Li Y, Gale M Jr, Katze MG. The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins. J Gen Virol 2003; 84: 535-543.
12. Hughes M, Griffin S, Harris M. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 2009; 90: 1329-1334.
13. Peng L, Liang D, Tong W, Li J, Yuan Z. Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem 2010; 285: 20870-20881.
14. Kriegs M, Burckstummer T, Himmelsbach K, Bruns M, Frelin L, Ahlen G, et al. The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 2009; 284: 28343-28351.
15. Wang C, Sarnow P, Siddiqui A. Translation of human hepatitis C virus RNA in cultured cells is mediated by an internal ribosome-binding mechanism. J Virol 1993; 67: 3338-3344.
16. Pacheco A, Martinez-Salas E. Insights into the biology of IRES elements through riboproteomic approaches. J Biomed Biotechnol 2010; 2010: 458927.
17. Kalliampakou KI, Kalamvoki M, Mavromara P. Hepatitis C virus (HCV) NS5A protein downregulates HCV IRES-dependent translation. J Gen Virol 2005; 86: 1015-1025.
18. Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, Arumugaswami V, et al. The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production. HEPATOLOGY 2009; 50: 1756-1764.
19. French SW, Dawson DW, Chen HW, Rainey RN, Sievers SA, Balatoni CE, et al. The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity. Cancer Lett 2007; 248: 198-210.
20. Arumugaswami V, Remenyi R, Kanagavel V, Sue EY, Ngoc Ho T, et al. High-resolution functional profiling of hepatitis C virus genome. PLoS Pathogens 2008; 4: e1000182.
21. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Peptide Protein Res 1990; 35: 161-214.
22. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004; 151: 1-44.
23. Gozdek A, Zhukov I, Polkowska A, Poznanski J, Stankiewicz-Drogon A, Pawlowicz JM, et al. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother 2008; 52: 393-401.
24. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005; 435: 374-379.
25. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007; 104: 12884-12889.
26. Chen YJ, Chen YH, Chow LP, Tsai YH, Chen PH, Huang CY, et al. Heat shock protein 72 is associated with the hepatitis C virus replicase complex and enhances viral RNA replication. J Biol Chem 2010; 285: 28183-28190.
27. Choi YW, Tan YJ, Lim SG, Hong W, Goh PY. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun 2004; 318: 514-519.
28. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 2009; 83: 4395-4403.
29. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Sci 2005; 62: 670-684.
30. Arakawa A, Handa N, Ohsawa N, Shida M, Kigawa T, Hayashi F, et al. The C-terminal BAG domain of BAG5 induces conformational changes of the Hsp70 nucleotide-binding domain for ADP-ATP exchange. Structure 2010; 18: 309-319.
31. Polier S, Dragovic Z, Hartl FU, Bracher A. Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding. Cell 2008; 133: 1068-1079.
32. Vembar SS, Jin Y, Brodsky JL, Hendershot LM. The mammalian Hsp40 ERdj3 requires its Hsp70 interaction and substrate-binding properties to complement various yeast Hsp40-dependent functions. J Biol Chem 2009; 284: 32462-32471.
33. Foster TL, Belyaeva T, Stonehouse NJ, Pearson AR, Harris M. All three domains of the hepatitis C virus nonstructural NS5A protein contribute to RNA binding. J Virol 2010; 84: 9267-9277.
34. Cornivelli L, Zeidan Q, De Maio A. HSP70 interacts with ribosomal subunits of thermotolerant cells. Shock 2003; 20: 320-325.